This study is looking at how a medication called Semaglutide, combined with different levels of health behavior and lifestyle treatment (HBLT), can help teenagers aged 12 to 18 who are living with obesity. The study aims to see if Semaglutide can reduce the need for very intensive HBLT by changing how the body handles appetite and cravings. All participants will receive Semaglutide. Researchers will measure changes in Body Mass Index (BMI) after 24 months to see how well the treatments work. You can join if you are 12 to under 18 years old, have a BMI at or above the 95th percentile for your age and sex, and can connect to virtual sessions with a device. People with type 1 or type 2 diabetes cannot participate.

Study design

This is an interventional study planning to enroll 1020 participants. It compares three different doses of health behavior and lifestyle treatment (HBLT) alongside Semaglutide.

What's involved

You will receive treatment with Semaglutide and participate in virtual platform sessions with video. The primary outcome is measured at 24 months.

Compensation

Not stated in the trial record.

Follow-up

Your Body Mass Index (BMI) will be measured at 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.